Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy

• Published in: Expert review of anti-infective therapy Vol. 18; no. 9; p. 947
• Main Authors: Ghanem, Samar E, Elsabaawy, Maha, Shebl, Nashwa, Abdelsameea, Eman, Othman, Warda, El-Bassal, Fathia I, Elgedawy, Gamalat A, Elsabaawy, Dalia M, Helal, Marwa L
• Format: Journal Article
• Language: English
• Published: England 01.09.2020
• Subjects: Adult; Antiviral Agents - administration & dosage; Carbamates - administration & dosage; Case-Control Studies; Drug Resistance, Viral; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus - genetics; Hepacivirus - isolation & purification; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Humans; Imidazoles - administration & dosage; Interferons - administration & dosage; Interferons - genetics; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines - administration & dosage; Ribavirin - administration & dosage; Sofosbuvir - administration & dosage; Treatment Outcome; Valine - administration & dosage; Valine - analogs & derivatives; Egypt; Direct acting antiviral drugs; HCV; single nucleotide polymorphism; IFNL3; therapy response
• ISSN: 1744-8336
• DOI: 10.1080/14787210.2020.1771180

: Despite the outstanding results of direct-acting antiviral therapies (DAAs) of Hepatitis C infection (HCV), non-responders had to be more defined. : assess the outcome of DAAs in linkage with Interferon lambda 3 (IFNL3) in HCV patients. : This case-control-study was conducted on 495 chronic-HCV (genotype-4a), previously treated Egyptians by either DAAs (responders 195, 120 relapsers) or interferon/ribavirin (IFN/RBV) (140 responders, 60 relapsers), and 98 healthy controls. IFNL3 distribution, clinical and laboratory data were assessed. : CT was the most predominant genotype in Egyptians (51%). All genotypes were sensitive to DAAs mainly CT genotype (60%), even TT genotype (resistant to IFN/RBV 40%) had 29.2% sensitivity. CT genotype was predominant in sofosbuvir/Daclatasvir responders (67.6%) (OR = 0.66), while non-CT prevailed in relapsers (56.7%). TT genotype may respond to SOF/Ledi better than other regimens (66.7%). In IFN/RBV relapsers; CT genotype was commoner (50%) than others, while CC genotype predominated in responders (54.3%). The c allele was the commonest in responders to IFN/RBV (71.4%), while the T allele was resistant to treatment (65% in relapsers). Addition of RBV to SOF/DCV reported higher resistance with CT genotype (42.2%-50%) and TT genotype (17.8%-27.8%). : This study recommended IFNL3 genotyping to be a prerequisite before stratifying treatment for HCV-4a Egyptians.